DK0607776T3 - Anvendelse af leflunomid til inhibering af tumornekrosefaktor alfa - Google Patents

Anvendelse af leflunomid til inhibering af tumornekrosefaktor alfa

Info

Publication number
DK0607776T3
DK0607776T3 DK94100016T DK94100016T DK0607776T3 DK 0607776 T3 DK0607776 T3 DK 0607776T3 DK 94100016 T DK94100016 T DK 94100016T DK 94100016 T DK94100016 T DK 94100016T DK 0607776 T3 DK0607776 T3 DK 0607776T3
Authority
DK
Denmark
Prior art keywords
necrosis factor
factor alpha
leflunomide
tumor necrosis
inhibit tumor
Prior art date
Application number
DK94100016T
Other languages
English (en)
Inventor
Klaus Ulrich Dr Weithmann
Robert Ryder Dr Bartlett
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of DK0607776T3 publication Critical patent/DK0607776T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK94100016T 1993-01-08 1994-01-03 Anvendelse af leflunomid til inhibering af tumornekrosefaktor alfa DK0607776T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4300280 1993-01-08

Publications (1)

Publication Number Publication Date
DK0607776T3 true DK0607776T3 (da) 1999-08-16

Family

ID=6477855

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94100016T DK0607776T3 (da) 1993-01-08 1994-01-03 Anvendelse af leflunomid til inhibering af tumornekrosefaktor alfa

Country Status (8)

Country Link
US (1) US5547970A (da)
EP (1) EP0607776B1 (da)
JP (1) JPH06234637A (da)
AT (1) ATE174219T1 (da)
DE (1) DE59407414D1 (da)
DK (1) DK0607776T3 (da)
ES (1) ES2124801T3 (da)
GR (1) GR3029490T3 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
AU3130597A (en) * 1996-05-16 1997-12-05 Duke University Tristetraprolin
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
DE19702988A1 (de) * 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
DE59801792D1 (de) * 1997-08-08 2001-11-22 Aventis Pharma Gmbh Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid
US7691890B2 (en) 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
DE69937904T2 (de) * 1998-03-11 2009-01-02 James W. Oak Park Williams Antivirale verwendungen von leflunomid produkten
US6184246B1 (en) 1999-07-30 2001-02-06 The United States Of America As Represented By The Secretary Of Agriculture Inhibition of cytokine production by polymethoxylated flavones
CA2451955C (en) 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
WO2003002187A2 (en) * 2001-06-26 2003-01-09 Photomed Technologies, Inc. Multiple wavelength illuminator
JP2006517191A (ja) * 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
JP2008500393A (ja) * 2004-05-21 2008-01-10 ザ ユーエービー リサーチ ファンデーション ピリミジン合成インヒビターに関する組成物および方法
US9662347B2 (en) 2010-05-11 2017-05-30 Gachon University Of Industry-Academic Cooperation Foundation Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5494911A (en) * 1990-05-18 1996-02-27 Hoechst Aktiengesellschaft Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
ATE197646T1 (de) * 1990-08-06 2000-12-15 Chiron Corp Verfahren zum nachweis von cytokinkonvertasehemmern

Also Published As

Publication number Publication date
JPH06234637A (ja) 1994-08-23
ES2124801T3 (es) 1999-02-16
EP0607776A2 (de) 1994-07-27
US5547970A (en) 1996-08-20
EP0607776A3 (da) 1994-08-31
ATE174219T1 (de) 1998-12-15
DE59407414D1 (de) 1999-01-21
EP0607776B1 (de) 1998-12-09
GR3029490T3 (en) 1999-05-28

Similar Documents

Publication Publication Date Title
DK0607776T3 (da) Anvendelse af leflunomid til inhibering af tumornekrosefaktor alfa
DK0607775T3 (da) Anvendelse af leflunomid til inhibering af interleukin 1 beta
DE122006000010I1 (de) Benzocyclobutyl- oder Indanyl-Alkyl-Amino-Alkyl substituierte 3- Benzazepin-2-ones, verwendbar in der Behandlung von kardiovaskularen Krankheiten
BR9805544A (pt) Uso de um composto.
ATE63906T1 (de) 3,5-disubstituierte 4,5-dihydroisoxazole als transglutaminasehemmer.
ATE210440T1 (de) Behandlung von tumoren mit verbindungen mit einer rxr-retinoid agonistische wirkung
EA200100772A1 (ru) Бензогетероциклы и их применение в качестве мек ингибиторов
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE88890T1 (de) D-cycloserin und d-alanin enthaltende mischung zur verbesserung des gedaechtnisses und des lernvermoegens oder zur behandlung von kognitiven und psychotischen erkrankungen.
PT705100E (pt) Guanidinas substituidas terapeuticas
BRPI0410979A (pt) composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
SE8104625L (sv) Anvending av aromatas-hemmare for profylax och terapi av prostatahyperplasi
DK0607777T3 (da) Anvendelse af leflunomid til inhibering af interleukin 8
FI820115L (fi) Tetrahydronaftalen- och indanfoereningar
DK0696283T3 (da) 2-, 3,- 4,- 5,- 6,- 7,- 8,- 9,- og/eller 10 substituerede dibenzoxazepinforbindelser, lægemidler og anvendelser
ES2068194T3 (es) Alfa-aminoacidos substituidos que tienen actividad farmaceutica.
DK472688A (da) Anvendelse af bezafibrat til behandling af diabetes
FI891986A (fi) Farmaceutiska sammansaettningar foer behandling av psoriasis.
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
DK0607774T3 (da) Anvendelse af leflunomid til inhibering af interleukin 1 alfa
ATE181240T1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
ATE342352T1 (de) Entwurf und verwendung von verbesserten zink- chelatbildenden peptiden zur regulation von matrix-metalloproteinasen
DE3861494D1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
DE3684825D1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
DE3770133D1 (de) Arzneimittel zur behandlung und prophylaxe von leber- und nierenkrankheiten.